复宏汉霖(02696.HK)与雅培制药就“汉斯状”销售新增许可区域

阿斯达克财经
Feb 24

复宏汉霖(02696.HK) 公布,与KGBio订立修订及部分终止协议,终止就汉斯状(斯鲁利单抗注射液)于除印尼以外其他地区的独家许可权利。同时,公司与雅培制药Abbott(ABT.US)  订立许可协议修订本,进一步扩大该产品的许可区域,包括原先与KGBio协议的地区。新增许可区域包括亚洲、中东、非洲及东欧等共42个国家及地区。Abbott将向公司额外支付监管里程碑款项合计不超过4,600万美元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10